Nashville, Tenn., January 13, 2026 — Revance and Teoxane announced that the U.S. Food and Drug Administration has approved RHA® Dynamic Volume from the Teoxane RHA® Collection for cheek augmentation and the correction of age-related midface contour deficiencies in adults aged 22 years and older. Formerly known as RHA® 4 Mepi, the product demonstrated robust safety and efficacy over a 52-week Phase III clinical program, supporting its formal U.S. launch in Q1 2026.
Science Significance
RHA® Dynamic Volume represents a next-generation hyaluronic acid (HA) dermal filler engineered to provide dynamic contour enhancement and structural support while maintaining natural facial movement. Powered by Preserved Network Technology (PNT)—a gentle, heatless, homogeneous crosslinking process—the gel preserves the intrinsic HA network, delivering high dynamic strength, stretch, and tissue integration. In a prospective, randomized, double-blinded, multicenter head-to-head Phase III study, the product demonstrated comparable effectiveness to Juvéderm Voluma XC, with fewer treatment sessions and touch-ups needed to achieve similar outcomes. Importantly, more than 94% of participants reported natural-looking and natural-feeling results at rest and in motion through one year, underscoring the filler’s rheological profile optimized for dynamic facial anatomy.
Regulatory Significance
The FDA approval affirms compliance with rigorous U.S. regulatory standards for injectable medical devices, validating clinical safety, durability, and performance in a challenging anatomical indication. The absence of late-onset or serious treatment-related adverse events, including no granulomas or delayed inflammatory responses, strengthens confidence in the product’s risk–benefit profile. This decision also reflects regulatory recognition of contemporary midface treatment paradigms, including multilayer volumization across superficial and deep fat compartments, aligning device labeling with current clinical practice.
Business Significance
Advertisement
For Revance and Teoxane, the approval marks a strategic expansion of the Teoxane RHA® Collection in the U.S. market and a second major advancement following the integration of mepivacaine across the portfolio. The new midface indication broadens addressable patient populations, enhances portfolio differentiation, and supports commercial momentum in the competitive aesthetics landscape. The head-to-head data versus an established comparator further strengthens market positioning, while the planned Q1 2026 launch sets the stage for near-term revenue impact and provider adoption.
Patients’ Significance
For patients, FDA approval translates to access to a clinically validated option that offers lasting volume restoration, natural expressiveness, and high satisfaction across attributes such as youthfulness, contour, symmetry, and smoothness. The demonstrated ability to achieve outcomes with fewer sessions may reduce treatment burden, while the favorable safety profile provides reassurance for individuals seeking aesthetic correction of age-related midface volume loss without compromising facial movement.
Policy Significance
From a policy and practice standpoint, the approval supports evidence-based adoption of advanced HA technologies and reinforces the importance of well-designed comparative clinical trials in device evaluation. It also highlights the FDA’s role in keeping pace with innovation in medical aesthetics while maintaining patient safety and quality standards, contributing to consistent regulatory expectations for future injectable device submissions.
The FDA approval of RHA® Dynamic Volume underscores a meaningful convergence of science, regulation, and clinical practice in medical aesthetics. Backed by 52-week Phase III data, a favorable safety profile, and validated real-world-relevant outcomes, the product is positioned to advance midface contour correction while preserving natural facial dynamics. As Revance and Teoxane prepare for a Q1 2026 launch, this milestone reinforces the growing role of innovative, regulator-validated technologies in delivering patient-centric aesthetic care.
Source: Revance and Teoxane press release
